Tomko Rachel L, Gray Kevin M, Huestis Marilyn A, Squeglia Lindsay M, Baker Nathaniel L, McClure Erin A
Department of Psychiatry and Behavioral Sciences, Medical university of South Carolina.
Institute of Emerging Health Professions, Thomas Jefferson University.
Curr Addict Rep. 2019 Dec;6(4):429-436. doi: 10.1007/s40429-019-00290-y. Epub 2019 Nov 19.
Cannabis abstinence traditionally is the primary outcome in cannabis use disorder (CUD) treatment trials. Due to the changing legality of cannabis, patient goals, and preliminary evidence that suggests individuals who reduce their cannabis use may show functional improvements, cannabis reduction is a desirable alternative outcome in CUD trials. We review challenges in measuring cannabis reduction and the evidence to support various definitions of reduction.
Reduction in number of cannabis use days was associated with improvements in functioning across several studies. Reductions in quantity of cannabis used was inconsistently associated with improvements in functioning, though definitions of quantity varied across studies. Different biomarkers may be used depending on the reduction outcome.
Biologically-confirmed reductions in frequency of cannabis use days may represent a viable endpoint in clinical trials for cannabis use disorder. Additional research is needed to better quantify reduction in cannabis amounts.
传统上，大麻戒断是大麻使用障碍（CUD）治疗试验的主要结果。由于大麻合法性的变化、患者目标以及初步证据表明减少大麻使用的个体可能会出现功能改善，大麻减少是CUD试验中一个理想的替代结果。我们回顾了衡量大麻减少的挑战以及支持各种减少定义的证据。
在多项研究中，大麻使用天数的减少与功能改善相关。尽管不同研究中对大麻使用量的定义各不相同，但大麻使用量的减少与功能改善之间的关联并不一致。根据减少结果的不同，可以使用不同的生物标志物。
经生物学确认的大麻使用天数频率降低可能是大麻使用障碍临床试验中的一个可行终点。需要进一步的研究来更好地量化大麻用量的减少。
